Page last updated: 2024-10-25

cimetidine and Adamantiades-Behcet Disease

cimetidine has been researched along with Adamantiades-Behcet Disease in 1 studies

Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.

Research Excerpts

ExcerptRelevanceReference
"On the fifth day of cimetidine therapy, agranulocytosis (800/ml) and a very low platelet count (40,000/ml) were observed; bone-marrow failure was documented both by biopsy and aspiration."1.26Association of cimetidine and bone-marrow suppression in man. ( Druart, F; Frocrain, C; Martin, J; Matuchansky, C; Metois, P, 1979)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Druart, F1
Frocrain, C1
Metois, P1
Martin, J1
Matuchansky, C1

Other Studies

1 other study available for cimetidine and Adamantiades-Behcet Disease

ArticleYear
Association of cimetidine and bone-marrow suppression in man.
    Digestive diseases and sciences, 1979, Volume: 24, Issue:9

    Topics: Adult; Agranulocytosis; Behcet Syndrome; Biopsy; Blood Cell Count; Bone Marrow; Cimetidine; Female;

1979